Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications

Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High concentration of this pleiotropic cytokine accounts for hyperinflammation and cytokine storm, and is related to multi-organ fa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jamal Majidpoor, Keywan Mortezaee
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Interleukin-6 (IL-6) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Inflammation Pneumonia Cytokine storm Cancer Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/93e52cbc24304340ac1dd23668576d21
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93e52cbc24304340ac1dd23668576d21
record_format	dspace
spelling	oai:doaj.org-article:93e52cbc24304340ac1dd23668576d212021-11-14T04:30:35ZInterleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications0753-332210.1016/j.biopha.2021.112419https://doaj.org/article/93e52cbc24304340ac1dd23668576d212022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221012051https://doaj.org/toc/0753-3322Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High concentration of this pleiotropic cytokine accounts for hyperinflammation and cytokine storm, and is related to multi-organ failure in patients with SARS-CoV-2 induced disease. IL-6 promotes lymphopenia and increases C-reactive protein (CRP) in such cases. However, blockade of IL-6 is not a full-proof of complete response. Hypoxia, hypoxemia, aberrant angiogenesis and chronic inflammation are inter-related events occurring as a response to the SARS-CoV-2 stimulatory effect on high IL-6 activity. Taking both pro- and anti-inflammatory activities will make complex targeting IL-6 in patient with SARS-CoV-2 induced disease. The aim of this review was to discuss about interactions occurring within the body of patients with SARS-CoV-2 induced disease who are representing high IL-6 levels, and to determine whether IL-6 inhibition therapy is effective for such patients or not. We also address the interactions and targeted therapies in cancer patients who also have SARS-CoV-2 induced disease.Jamal MajidpoorKeywan MortezaeeElsevierarticleInterleukin-6 (IL-6)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)InflammationPneumoniaCytokine stormCancerTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112419- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Interleukin-6 (IL-6) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Inflammation Pneumonia Cytokine storm Cancer Therapeutics. Pharmacology RM1-950
spellingShingle	Interleukin-6 (IL-6) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Inflammation Pneumonia Cytokine storm Cancer Therapeutics. Pharmacology RM1-950 Jamal Majidpoor Keywan Mortezaee Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
description	Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High concentration of this pleiotropic cytokine accounts for hyperinflammation and cytokine storm, and is related to multi-organ failure in patients with SARS-CoV-2 induced disease. IL-6 promotes lymphopenia and increases C-reactive protein (CRP) in such cases. However, blockade of IL-6 is not a full-proof of complete response. Hypoxia, hypoxemia, aberrant angiogenesis and chronic inflammation are inter-related events occurring as a response to the SARS-CoV-2 stimulatory effect on high IL-6 activity. Taking both pro- and anti-inflammatory activities will make complex targeting IL-6 in patient with SARS-CoV-2 induced disease. The aim of this review was to discuss about interactions occurring within the body of patients with SARS-CoV-2 induced disease who are representing high IL-6 levels, and to determine whether IL-6 inhibition therapy is effective for such patients or not. We also address the interactions and targeted therapies in cancer patients who also have SARS-CoV-2 induced disease.
format	article
author	Jamal Majidpoor Keywan Mortezaee
author_facet	Jamal Majidpoor Keywan Mortezaee
author_sort	Jamal Majidpoor
title	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
title_short	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
title_full	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
title_fullStr	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
title_full_unstemmed	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
title_sort	interleukin-6 in sars-cov-2 induced disease: interactions and therapeutic applications
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/93e52cbc24304340ac1dd23668576d21
work_keys_str_mv	AT jamalmajidpoor interleukin6insarscov2induceddiseaseinteractionsandtherapeuticapplications AT keywanmortezaee interleukin6insarscov2induceddiseaseinteractionsandtherapeuticapplications
_version_	1718429970307481600

Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications

Ejemplares similares